Cybin Inc. to Present at H.C. Wainwright Global Investment Conference
TL;DR
Cybin's CBO fireside chat at H.C. Wainwright conference offers investors early insights into breakthrough neuropsychiatry treatments with significant market potential.
Cybin is developing CYB003 and CYB004 through Phase 3 and Phase 2 clinical trials respectively for treating major depressive disorder and anxiety.
Cybin's innovative mental health treatments aim to provide effective and durable results for patients suffering from unmet mental health needs.
Cybin uses deuterated psilocin and DMT analogs in clinical trials to revolutionize neuropsychiatry treatment approaches.
Found this article helpful?
Share it with your network and spread the knowledge!
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company, announced that Chief Business Officer George Tziras will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 11:00 a.m. ET. This presentation provides investors and industry stakeholders with insights into Cybin's progress in developing next-generation mental health treatments.
The company is developing CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for the adjunctive treatment of major depressive disorder. CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to address significant unmet medical needs. Additionally, Cybin is advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The company maintains a research pipeline of investigational, 5-HT-receptor focused compounds aimed at revolutionizing mental healthcare.
Cybin's participation in this major investment conference underscores the growing importance of innovative neuropsychiatry treatments in addressing the global mental health crisis. With mental health conditions affecting millions worldwide and current treatment options often proving inadequate, Cybin's novel approaches could potentially transform patient care. The company's breakthrough therapy designation and advanced clinical trials position it at the forefront of mental health treatment innovation.
Investors and industry observers can access additional information through the company's newsroom at https://ibn.fm/CYBN. The conference presentation represents an opportunity for Cybin to demonstrate its progress in developing effective and durable treatment options for mental health conditions, potentially impacting both patient outcomes and the broader healthcare landscape.
Curated from InvestorBrandNetwork (IBN)
